Methods for non-proportional hazards in clinical trials: A systematic review

被引:6
作者
Bardo, Maximilian [1 ]
Huber, Cynthia [1 ]
Benda, Norbert [1 ,2 ]
Brugger, Jonas [3 ]
Fellinger, Tobias [4 ]
Galaune, Vaidotas [5 ]
Heinz, Judith [1 ]
Heinzl, Harald [6 ]
Hooker, Andrew C. [5 ]
Klinglmueller, Florian [4 ]
Koenig, Franz [3 ]
Mathes, Tim [1 ]
Mittlboeck, Martina [6 ]
Posch, Martin [3 ]
Ristl, Robin [3 ]
Friede, Tim [1 ]
机构
[1] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
[2] Fed Inst Drugs & Med Devices, Bonn, Germany
[3] Med Univ Vienna, Ctr Med Data Sci, Sect Med Stat, Vienna, Austria
[4] Agentur Gesundheit & Ernahrungssicherheit AGES, Vienna, Austria
[5] Uppsala Univ, Dept Pharm, Uppsala, Sweden
[6] Med Univ Vienna, Ctr Med Data Sci, Sect Clin Biometr, Vienna, Austria
关键词
Cox model; log-rank test; survival analysis; right-censored observations; non-proportional hazards; SURVIVAL; AVERAGE; RATIO; TESTS; TERM;
D O I
10.1177/09622802241242325
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
For the analysis of time-to-event data, frequently used methods such as the log-rank test or the Cox proportional hazards model are based on the proportional hazards assumption, which is often debatable. Although a wide range of parametric and non-parametric methods for non-proportional hazards has been proposed, there is no consensus on the best approaches. To close this gap, we conducted a systematic literature search to identify statistical methods and software appropriate under non-proportional hazard. Our literature search identified 907 abstracts, out of which we included 211 articles, mostly methodological ones. Review articles and applications were less frequently identified. The articles discuss effect measures, effect estimation and regression approaches, hypothesis tests, and sample size calculation approaches, which are often tailored to specific non-proportional hazard situations. Using a unified notation, we provide an overview of methods available. Furthermore, we derive some guidance from the identified articles.
引用
收藏
页码:1069 / 1092
页数:24
相关论文
共 46 条
  • [1] Aalen OO, 2008, STAT BIOL HEALTH, P1
  • [2] Allignol A., 2022, CRAN TASK VIEW SURVI
  • [3] Critical review of oncology clinical trial design under non-proportional hazards
    Ananthakrishnan, Revathi
    Green, Stephanie
    Previtali, Alessandro
    Liu, Rong
    Li, Daniel
    LaValley, Michael
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 162
  • [4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [5] Boulesteix A. L., 2020, Significance, V17, P18, DOI DOI 10.1111/1740-9713.01444
  • [6] Testing Treatment Effect in Randomized Clinical Trials With Possible Nonproportional Hazards
    Callegaro, Andrea
    Spiessens, Bart
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (02): : 204 - 211
  • [7] Quantifying the average of the time-varying hazard ratio via a class of transformations
    Chen, Qingxia
    Zeng, Donglin
    Ibrahim, Joseph G.
    Chen, Ming-Hui
    Pan, Zhiying
    Xue, Xiaodong
    [J]. LIFETIME DATA ANALYSIS, 2015, 21 (02) : 259 - 279
  • [8] Dehbi HM., 2017, BMJ CLIN RES ED, V357
  • [9] CASANOVA: Permutation inference in factorial survival designs
    Ditzhaus, Marc
    Genuneit, Jon
    Janssen, Arnold
    Pauly, Markus
    [J]. BIOMETRICS, 2023, 79 (01) : 203 - 215
  • [10] More powerful logrank permutation tests for two-sample survival data
    Ditzhaus, Marc
    Friedrich, Sarah
    [J]. JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION, 2020, 90 (12) : 2209 - 2227